Among children with high blood pressure (BP), there are racial and ethnic disparities in receipt of nutrition, lifestyle, and weight counseling.

Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

On February 7, the NIH announced that it would begin capping indirect cost payments for new and existing research grants at 15%.

Compared with thrombotic stroke, hemorrhagic stroke has more than double the odds of diagnostic delay in pregnant and postpartum patients.

Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a study.

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Patients with diabetic DED can experience inflammatory biomarker reductions and sign and symptom improvements with topical insulin.

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

Higher FT4 levels were associated with increased risks for knee OA prevalence, severity, and progression, especially among patients with greater joint loading.

A positive response to treatment for pediatric obesity has enduring health benefits into young adulthood, according to a study.